Evidence map›Paper›PMID 32297988›Full record

SynthesisJournal of medical virology2020

Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.

Phulen Sarma, Hardeep Kaur, Harish Kumar, Dhruv Mahendru, Pramod Avti, Anusuya Bhattacharyya, Manisha Prajapat, Nishant Shekhar, Subodh Kumar, Rahul Singh and 4 more

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of medical virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 26 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 26 pooled it
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 26 syntheses or guidelines pooled it, 201 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021
    Pooled it
  10. Pooled it
  11. Is there any potential management against COVID-19? A systematic review and meta-analysis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Phulen SarmaDepartment of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.
Hardeep KaurDepartment of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.ORCID 0000-0003-2419-1887
Harish KumarDepartment of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.
Dhruv MahendruDepartment of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.
Pramod AvtiDepartment of Biophysics, Post Graduate Institute of Medical Research, Chandigarh, India.ORCID 0000-0001-5603-4523
Anusuya BhattacharyyaDepartment of Ophthalmology, Government Medical College and Hospital, Chandigarh, India.
Manisha PrajapatDepartment of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.
Nishant ShekharDepartment of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.
Subodh KumarDepartment of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.
Rahul SinghDepartment of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.
Ashutosh SinghDepartment of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.
Deba Prasad DhibarDepartment of Internal medicine, Post Graduate Institute of Medical Research, Chandigarh, India.
Ajay PrakashDepartment of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.
Bikash MedhiDepartment of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.ORCID 0000-0002-4017-641X
Post Graduate Institute of Medical Education and Research · INGovernment Medical College and Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the demonstration of the efficacy of hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 in vitro, many trials started to evaluate its efficacy in clinical settings. However, no systematic review and meta-analysis have addressed the issue of the safety and efficacy of hydroxychloroquine (HCQ) in coronavirus disease 2019. We conducted a systematic review and meta-analysis with the objectives of evaluation of safety and efficacy of HCQ alone or in combination in terms of "time to clinical cure," "virological cure," "death or clinical worsening of disease," "radiological progression," and safety. RevMan was used for meta-analysis. We searched 16 literature databases out of which seven studies (n = 1358) were included in the systematic review. In terms of clinical cure, two studies reported possible benefit in "time to body temperature normalization" and one study reported less "cough days" in the HCQ arm. Treatment with HCQ resulted in less number of cases showing the radiological progression of lung disease (odds ratio [OR], 0.31, 95% confidence interval [CI], 0.11-0.9). No difference was observed in virological cure (OR, 2.37, 95% CI, 0.13-44.53), death or clinical worsening of disease (OR, 1.37, 95% CI, 1.37-21.97), and safety (OR, 2.19, 95% CI, 0.59-8.18), when compared with the control/conventional treatment. Five studies reported either the safety or efficacy of HCQ + azithromycin. Although seems safe and effective, more data are required for a definitive conclusion. HCQ seems to be promising in terms of less number of cases with radiological progression with a comparable safety profile to control/conventional treatment. We need more data to come to a definite conclusion.

Indexed as

PandemicsAntiviral AgentsAzithromycinBetacoronavirusClinical Trials as TopicCoronavirus InfectionsCOVID-19Drug Therapy, CombinationHumansHydroxychloroquinePneumonia, ViralSARS-CoV-2Treatment OutcomeViral LoadVirus ReplicationAntiviral AgentsAzithromycinHydroxychloroquine2019-nCoVCOVID-19hydroxychloroquinemeta-analysisSARS CoV-2

Identifiers

PMID32297988
PMCPMC7262144
OpenAlexW3016626550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.